HONG KONG — A new peptide-based drug delivery system has been shown for the first time to enable therapeutic proteins and possibly other drugs to cross the blood-brain barrier (BBB), which may help in treating multiple sclerosis (MS) and other central nervous system (CNS) disorders such as Alzheimer's disease and Parkinson's disease, Korean researchers reported.